Insights into the Targeting Potential of Thymoquinone for Therapeutic Intervention Against Triple-negative Breast Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|19|1|70-80

ISSN： 1389-4501

Source： Current Drug Targets, Vol.19, Iss.1, 2018-01, pp. : 70-80

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment

By  

Current Drug Delivery, Vol. 15, Iss. 3, 2018-03 ,pp. : 406-416

Bentham Science Publishers

Access to resources Recommend Favorite

Triple-Negative Breast Cancer: Epidemiology and Management Options

By Dawood Shaheenah  

Drugs, Vol. 70, Iss. 17, 2010-12 ,pp. : 2247-2258

Adis International

Access to resources Recommend Favorite

Subtyping of triple-negative breast cancer: Implications for therapy

By Abramson Vandana G.   Lehmann Brian D.   Ballinger Tarah J.   Pietenpol Jennifer A.  

Cancer, Vol. 121, Iss. 1, 2015-01 ,pp. : 8-16

Blackwell Publishing

Access to resources Recommend Favorite

Advances in the Treatment of Triple-negative Early Breast Cancer

By  

Medicinal Chemistry, Vol. 12, Iss. 3, 2016-05 ,pp. : 268-272

Bentham Science Publishers

Access to resources Recommend Favorite

FOXP2 Promotes Tumor Proliferation and Metastasis by Targeting GRP78 in Triple-negative Breast Cancer

By  

Current Cancer Drug Targets, Vol. 18, Iss. 4, 2018-04 ,pp. : 382-389

Bentham Science Publishers

Access to resources Recommend Favorite